Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)

v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Research and development $ 4,766,832 $ 1,730,000 $ 8,254,079 $ 3,373,375
General and administrative 1,877,831 1,504,295 3,615,837 3,082,737
Total operating expenses 6,644,663 3,234,295 11,869,916 6,456,112
Income (loss) from operations (6,644,663) (3,234,295) (11,869,916) (6,456,112)
Other income (loss) 32,158 0 32,158 0
Interest income (loss) 1,299,205 780,769 2,631,408 1,377,614
Net income (loss) (5,313,300) (2,453,526) (9,206,350) (5,078,498)
Other comprehensive income (loss):        
Foreign currency translation gain (loss), net 516 (3,456) 326 (3,847)
Unrealized gain (loss) on investments, net (7,721) 102,817 (40,398) 45,432
Comprehensive income (loss) $ (5,320,505) $ (2,354,165) $ (9,246,423) $ (5,036,913)
Net income (loss) per share:        
Basic and diluted (in dollars per share) $ (0.62) $ (0.35) $ (1.08) $ (0.73)
Weighted average shares outstanding:        
Basic and diluted (in shares) [1] 8,542,450 6,998,082 8,538,966 6,992,761
[1] Pre-funded warrants outstanding during the three and six months ended June 30, 2026 and 2025, are exercisable at a nominal price and are considered, in substance, equivalent to outstanding common stock. Accordingly, such pre-funded warrants have been included in the calculation of weighted-average shares of common stock outstanding for purposes of basic and diluted net income (loss) per share.